In this sense, the strong antigenicity of hPSMA in mice would explain why only in the B16-PSMA model the CART/STING-L treatment induced vitiligo (indicative of epitope spreading to melanocyte Ags) and yielded survivors resistant to B16-F10 rechallenge. The gene discussed is CARTPT; the disease is vitiligo.